These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38459763)

  • 1. What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.
    Assefa GM; Roberts JA; Mohammed SA; Sime FB
    J Antimicrob Chemother; 2024 May; 79(5):946-958. PubMed ID: 38459763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.
    Crass RL; Pai MP
    Pharmacotherapy; 2019 Feb; 39(2):182-195. PubMed ID: 30589457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
    Gatti M; Pea F
    Expert Rev Clin Pharmacol; 2021 May; 14(5):583-599. PubMed ID: 33687300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avibactam Pharmacokinetic/Pharmacodynamic Targets.
    Nichols WW; Newell P; Critchley IA; Riccobene T; Das S
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610208
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
    Kidd JM; Stein GE; Nicolau DP; Kuti JL
    J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.
    Sy SKB; Derendorf H
    Clin Microbiol Infect; 2018 Jul; 24(7):707-715. PubMed ID: 28760708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
    Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
    Marsot A
    J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimising β -lactam Dosing in Neonates: A Review of Pharmacokinetics, Drug Exposure and Pathogens.
    Fuchs A; Li G; van den Anker JN; Bielicki J
    Curr Pharm Des; 2017; 23(38):5805-5838. PubMed ID: 28950814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.
    Dhaese S; Heffernan A; Liu D; Abdul-Aziz MH; Stove V; Tam VH; Lipman J; Roberts JA; De Waele JJ
    Clin Pharmacokinet; 2020 Oct; 59(10):1237-1250. PubMed ID: 32710435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility.
    Ferrer-Espada R; Sánchez-Gómez S; Pitts B; Stewart PS; Martínez-de-Tejada G
    Int J Antimicrob Agents; 2020 Jul; 56(1):105986. PubMed ID: 32335279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of optimal pharmacokinetic/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis.
    Robson C; Tan B; Stuart R; Nicholls S; Rogers BA; Sandaradura I
    J Antimicrob Chemother; 2023 Mar; 78(3):599-612. PubMed ID: 36691839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa.
    Fratoni AJ; Gethers ML; Nicolau DP; Kuti JL
    Clin Infect Dis; 2024 Jul; 79(1):33-42. PubMed ID: 38306487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.